The European Commission on Wednesday authorised a merger of US drug giant Pfizer's off-patent business unit with the pharmaceutical company Mylan to create a global powerhouse for lower-cost medicines.

The merger between Pfizer's Upjohn unit, based in China, and Netherlands-based Mylan will create a new company selling popular products such Viagra, the anti-cholesterol drug Lipitor and the anti-allergy injector EpiPen.

But it is conditional on Mylan divesting certain generic medicines, the Commission said in a statement.

Once effected, it would ensure the merger "does not harm competition, thus preserving competitive access to certain genericised medicines for national health services and European citizens," EU competition commissioner Margrethe Vestager said.

Mylan and Upjohn overlap in cardiovascular, genito-urinary, musculoskeletal, nervous system, and sensory organ treatments areas, but "no competition concerns arise for the majority of the products" both companies put out, the Commission said.

There were concerns only for 36 molecules used in their respective generic medicines in certain countries in Europe, requiring Mylan to offload those activities.

The merger, announced in July 2019, will see a new company formed with revenues of around $20 billion, in which Pfizer shareholders will take 57 percent of the equity and the Mylan shareholders the rest.

It came about as the generic medicine sector adapted to increased competition from laboratories in India.

zap/rmb/txw

MYLAN

PFIZER

Related Links
Hospital and Medical News at InternDaily.com

Tweet

Thanks for being here; We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain. With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords. Our news coverage takes time and effort to publish 365 days a year. If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor $5 Billed Once credit card or paypal		SpaceDaily Monthly Supporter $5 Billed Monthly paypal only

Fighting WHO, Trump hands China a PR opportunity
Washington (AFP) April 15, 2020
With his brash move to stop funding the World Health Organization in the midst of the coronavirus pandemic, President Donald Trump may score points at home but is handing an opportunity that China is delighted to exploit. Critics say Trump is eager to find a scapegoat as thousands of Americans die from COVID-19, even if there is broad agreement in Washington that the WHO was too eager to please China when the virus first emerged in the metropolis of Wuhan. Trump, who has fiercely criticized UN a ... read more